Guidelines for the management of community-acquired pneumonia in the elderly patient;Guía de manejo de la neumonía adquirida en la comunidad en el anciano

Revista Espanola de Quimioterapia

Volumn 27, Issue 1, 2014, Pages 69-86

  González Castillo, Juan ^a   Martín Sánchez, Francisco Javier ^b   Llinares, Pedro ^c   Menéndez, Rosario ^d   Mujal, Abel ^e   Navas, Enrique ^f   Barberán, José ^g  

^a Sociedad Española de Medicina de Urgencias y Emergencias   (Spain)

^b Medicina Preventiva y Salud Pública   (Spain)

^c Sociedad Española de Quimioterapia SEQ   (Spain)

^d Sociedad Española de Neumología y Cirugía Torácica   (Spain)

^e Sociedad Española de Hospitalización a Domicilio   (Spain)

^f Programa de Control de Calidad   (Spain)

^g Sóciedad Espanóla de Medicina Interna   (Spain)

Author keywords

Community acquired pneumonia; Diagnosis; Elderly; Guidelines; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANAEROBE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ENDOTRACHEAL INTUBATION; ENTEROBACTERIACEAE; FRAIL ELDERLY; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PALLIATIVE THERAPY; PATIENT CODING; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; RISK FACTOR; TREATMENT DURATION; VACCINATION; AGED; ANTIBIOTIC RESISTANCE; CASE MANAGEMENT; COMMUNITY-ACQUIRED INFECTIONS; MICROBIOLOGY; PNEUMONIA, BACTERIAL; PROGNOSIS; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE MANAGEMENT; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FRAIL ELDERLY; HOSPITALIZATION; HUMANS; PNEUMONIA, BACTERIAL; PROGNOSIS; RISK FACTORS;

EID: 84897064871     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. Capelastegui A, Espana PP, Bilbao A, Gamazo J, Medel F, Salgado J,. Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care. J Infect 2010; 61:364-71.
2. Welte T. Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis 2012; 31:33-47.
3. Martínez Ortiz de Zárate M, González del Castillo J, Julián Jiménez A, Piñera Salmerón P, Llopis Roca F, Guardiola Tey JM, et al. Estudio INFURG-SEMES: epidemiología de las infecciones en los servicios de urgencias hospitalarios y evolución durante la última década. Emergencias 2013; 25:368-78.
4. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000; 31:1066-78.
5. Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging 2006; 1:253-60.
6. Aguirre Tejedo A, Miró O, Jacob Rodríguez A, Herrero Puente P, Martín-Sánchez FJ, Alemany X, et al. Papel del factor precipitante de un episodio de insuficiencia cardiaca aguda en relación al pronóstico a corto plazo del paciente: estudio PAPRICA. Emergencias 2012; 24:438-46.
7. Torres A, Barberán J, Falguera M, Menéndez R, Molina J, Olaechea P,. Grupo de la Guía Multidisciplinar para el Manejo de la Neumonía Adquirida en la Comunidad. Med Clin (Barc) 2013; 140:223-41.
8. Mandell LA, Wunderink RG, Anzueto A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27-72.
9. Sternberg SA, Wershof Schwartz A, Karunananthan S, Bergman H, Mark Clarfield A. The identification of frailty: a systematic literature review. J Am Geriatr Soc 2011; 59:2129-38.
10. Martín-Sánchez, F.J., Fernández Alonso, C. and Merino, C. El paciente geriátrico en urgencias. An Sist Sanit Nav 2010; 33: S163-72.
11. Martín-Sánchez FJ, Fernández Alonso C, Gil Gregorio P. Key points in healthcare of frail elders in the Emergency Department. Med Clin (Barc) 2013; 140:24-9.
12. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173:489-95.
13. Cesáreo Fernández-Alonso, F Javier Martín-Sánchez. Geriatric assessment in frail older patients in the emergency department. Rev Clin Gerontol 2013; 23(04). DOI:10.1017/S0959259813000142
14. Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc 1991; 39:S8-16.
15. Conroy SP, Stevens T, Parker SG, Gladman JR. A systematic review of comprehensive geriatric assessment to improve outcomes for frail older people being rapidly discharged from acute hospital: 'interface geriatrics'. Age Ageing 2011; 40:436-43.
16. Ellis G, Whitehead MA, Robinson D, O'Neill D, Langhorne P. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ 2011; 343. doi: 10.1136/bmj.d6553.
17. Garcia-Vidal C, Viasus D, Roset A, Adamuz J, Verdaguer R, Dorca J, et al. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol Infect 2011; 17:1659-65.
18. Polverino E, Dambrava P, Cilloniz C, Balasso V, Marcos MA, Esquinas C,. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax 2010; 65:354-9.
19. Ewig S, Klapdor B, Pletz MW, Rohde G, Schutte H, Schaberg T, et al. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax 2012; 67:132-8.
20. Chalmers J, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, et al. Epidemiología, antibiotic therapy and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 201; 53:107-13.
21. Giannella M, Pinilla B, Capdevila JA, Martínez Alarcón J, Muñoz P, López Álvarez J, et al. Estudio de Neumonía En Medicina Interna study Group from the Sociedad Española de Medicina Interna. Pneumonia treated in the internal medicine department: focus on healthcare-associated pneumonia. Clin Microbiol Infect 2012; 18:786-94.
22. Micek ST, Kollef KE, Reichley RM. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007; 51: 3568-73.
23. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-62.
24. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 2009; 22: 316-25.
25. Torres A, Menendez R. Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty? Eur Respir J 2010; 35: 473-74.
26. Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to emergency deparment. Clin Infect Dis 2012; 54:193-8.
27. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012; 54:470-8.
28. Aliberti S, Cilloniz C, Chalmers J, Zanaboni AM, Cosentini R, Tarsia P,. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 2013; 68:997-9.
29. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H,. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 2013; 57:1373-83.
30. Polverino E, Torres Marti A. Community-acquired pneumonia. Minerva Anestesiol 2011; 77:196-211.
31. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010; 10:279-87.
32. Cabré P, Serra-Prat M, Palomera E, Almirall J, Pallares R, Clavé P. Prevalence and prognostic implications of dysphagia in elderly patients with pneumonia. Age Aging 2010; 39:39-45.
33. Kikuchi R, Watabe N, Konno T, Mishina N, Sekizawa K, Sasaki H. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150:251-3.
34. van der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM, Schols JM, de Baat C. Risk factores for aspiration pneumonia in frail patient. J Am Mer Dir Assoc 2011; 12: 244-54.
35. Taylor JK, Flemming GB, Singanayagam A, Hill AT, Chalmers J. Risk factors for aspiration in community-acquired pneumonia: analysis of hospitalized UK cohort. Am J Med 2013; 126:995-1001.
36. Fisch J, Lansing B, Wang L, Symons K, Cherian K, McNamara S, et al. New acquisition of antibiotic-resistant organisms in skilled nursing facilities. J Clin Microbiol 2012; 50:1698-703.
37. von Baum H, Welte T, Marre R, Suttorp N, Ewig S. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010; 35:598-605.
38. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006; 57:780-3.
39. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in non hospitalized patients. J Clin Microbiol 2004; 42:1089-94.
40. El-Solh A, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover, et al. Microbiology of Severe Aspiration Pneumonia in Institutionalized Elderly. Am J Respir Crit Care Med 2003; 167:1650-54.
41. Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011; 139:909-19.
42. Soler-Cataluña JJ, Piñera Salmerón P, Trigueros JA, Calle M, Almagro P, Molina J,. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC). Diagnóstico y tratamiento hospitalario de la agudización. Emergencias 2013; 25:301-17.
43. Menendez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodriguez de Castro F. Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR). Arch Bronconeumol 2010; 46:543-58.
44. Davison VE, Sanford BA. Adherence of staphylococcus aureus to influenza A virus-infected Madin-Darby canine kidney cell cultures. Infect Immun 1981; 32:118-26.
45. de Bentzmann S, Tristan A, Etienne J, Brousse N, Vandenesch F, Lina G. Staphylococcus aureus isolates associated with necrotizing pneumonia bind to basement membrane type I and IV collagens and laminin. J Infect Dis 2004; 190:1506-15.
46. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, Albrecht V, Limbago B, et al. Prevalence of methicillin-resistant S aureus as an etiology in community-acquired pneumonia. Clin Infect Dis 2012; 54:1126-33.
47. Obed M, García-Vidal C, Pessacq P, Mykietiuk A, Viasus D, Cazzola L, Clinical features and outcome of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Enferm Infecc Microbiol Clin 2014; 32:23-7.
48. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant S aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 2013;13: 268.
49. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000; 31:1066-78.
50. Berman P, Hogan DB, Fox RA. The atypical presentation of infection in old age. Age Ageing 1987; 16:201-207.
51. Lin RY, Heacock LC, Bhargave GA, Fogel JF. Clinical associations of delirium in hospitalized adult patients and the role of on admission presentation. Int J Geriatr Psychiatry 2010; 25:1022-9.
52. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998; 27:358-63.
53. Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2004; 117:305-11.
54. Self WH, Courtney DM, McNaughton CD, Wunderink RG, Kline JA. High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. Am J Emerg Med 2013; 31:401-5.
55. Franquet T. Imaging of pneumonia: trends and algorithms. Eur Respir J 2001; 18:196-208.
56. Thiem U, Niklaus D, Sehlhoff B, Stückle C, Heppner HJ, Endres HG, et al. C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. Age Ageing 2009; 38:693-7.
57. Stucker F, Herrmann F, Graf JD, Michel JP, Krause KH, Gavazzi G. Procalcitonin and infection in elderly patients. J Am Geriatr Soc 2005; 53:1392-5.
58. Julián Jiménez A, Parejo Miguez R, Cuena Boy R, Palomo De Los Reyes MJ, Laín Terés N, Lozano Ancín A. Intervenciones para mejorar el manejo de la neumonía adquirida en la comunidad desde el servicio de urgencias. Emergencias 2013; 25:379-92.
59. Tudela P, Prat C, Lacoma A, Maria Mòdol J, Domínguez J, Giménez M, et al. Biomarcadores para la predicción en urgencias de infección bacteriana, bacteriemia y gravedad. Emergencias 2012; 24:348-56.
60. Herrero Puente P, Fernández García D, Gil Román JJ, Prieto García B, Vázquez Álvarez J, Miguel Fernández D, et al. Estudio piloto de la utilidad de la región medial de la proadrenomedulina (RM-proADM) en la valoración de la disnea de origen respiratorio en urgencias. Emergencias 2012; 24:357-65.
61. Julián Jiménez A. Biomarcadores de infección en urgencias: ¿cuáles pueden sernos útiles?. Emergencias 2012; 24:343-5.
62. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T; German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict short and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010; 182:1426-34.
63. Renaud B, Schuetz P, Claessens YE, Labarère J, Albrich W, Mueller B. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia. Chest 2012; 142:1447-54.
64. Herrero Puente P, Fernández García D, Gil Román JJ, Prieto García B, Vázquez Álvarez J, Miguel Fernández D, et al. Estudio piloto de la utilidad de la región medial de la proadrenomedulina (RM-proADM) en la valoración de la disnea de origen respiratorio en urgencias. Emergencias 2012; 24:357-65.
65. Wood J, Butler CC, Hood K, Kelly MJ, Verheij T, Little P, et al. Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J 2011; 38:112-8.
66. Fernández-Sabé N, Rosón B, Carratalà J, Dorca J, Manresa F, Gudiol F. Clinical diagnosis of Legionella pneumonia revisited: evaluation of the Community-Based Pneumonia Incidence Study Group scoring system. Clin Infect Dis 2003; 37:483-9.
67. Ewan V, Perry JD, Mawson T, McCracken G, Brown AN, Newton J, et al. Detecting potential respiratory pathogens in the mouths of older people in hospital. Age Ageing 2010; 39:122-5.
68. Charles PG. Early diagnosis of lower respiratory tract infections (point-of-care tests). Curr Opin Pulm Med 2008; 14:176-82.
69. Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, et al; Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob Agents Chemother 2010; 54:2953-9.
70. Payeras A, Garau M, Villoslada A, Beingolea D, Sevillano A, Borras M, et al. Prevalencia, evolución y factores clínicos relacionados con infecciones por Streptococcus pneumoniae con resistencia a quinolonas (XIV Congreso de la Sociedad de Enfermedades Infecciosas y Microbiología Clínica (SEIMC); 19-22 mayo 2010; Barcelona, España.p186-7
71. Chen D.K, McGeer A, de Azavedo J.C, Low D.E, for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluorquinolones in Canada. N Engl J Med 1999; 341:233-239.
72. Roberts SM, Freeman AF, Harrington SM, Holland SM, Murray PR, Zelazny AM. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J 2006; 25:562-4.
73. Endimiani A, Blackford M, Dasenbrook EC, Reed MD, Bajaksouszian S, Hujer AM,. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother 2011; 55:1684-92.
74. Kainer MA, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis 2007;1 3:1024-30.
75. Johnson AP, Tysall L, Stockdale MV, Woodford N, Kaufmann ME, Warner M, et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002; 21:751-4.
76. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357:1179.
77. Sánchez García M, de la Torre MA, Morales G, Pelaez B, Tolón MJ, Domingo S, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260-4.
78. Mensa J, Soriano A, Llinares P, Barberán J, Montejo M, Salavert M, et al. Guía de tratamiento antimicrobiano de la infección por Staphylococcus aureus. Rev Esp Quimioter 2013; 26: S1-84.
79. Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009; 47:1012-20.
80. European Centre for Disease Prevention and Control (2012). Consultado el 1 de Marzo de 2014, de http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance /database/Pages/table_reports.aspx
81. Gill MM, Rao JU, Kaleem F, Hassan A, Khalid A, Anjum R. In vitro efficacy of colistin against multi-drug resistant Pseudomonas aeruginosa by minimum inhibitory concentration. Pak J Pharm Sci 2013; 26:7-10.
82. Cantón R, Loza E, Aznar J, Calvo J, Cercenado E, Cisterna R, et al; SMART-Spain Working Group. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010). Rev Esp Quimioter 2011; 24:223-32.
83. European Centre for Disease Prevention and Control (2012). Consultado el 4 de Diciembre de 2013, de http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_ resistance/database/Pages/table_reports.aspx
84. Cillóniz C, Ewing S, Polverino E, Marcos MA, Esquinas C, Gabarrús A,. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340-6.
85. Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H; German Lung Abscess Study Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36:23-30.
86. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34:1607-12.
87. Murcia JM, González-Comeche J, Marín A, Barberán J, Granizo JJ, Aguilar L, et al; SCAPE Study Group. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. Clin Microbiol Infect 2009; 15:1046-50.
88. Boyce JM, Pop OF, Abreu-Lanfranco O, Hung WY, Fisher A, Karjoo A,. A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother 2013; 57:1163-8.
89. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-9.
90. Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. Betalactam plus aminoglycoside or fluoroquinolone combination versus Betalactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 2013; 41:301-10.
91. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35: 1888-95.
92. Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013; 26:159-67.
93. Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA,. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63:447-52.
94. Bellmann-Weiler R, Weiss G. Pitfalls in the diagnosis and therapy of infections in elderly patients--a mini-review. Gerontology 2009; 55:241-9.
95. Thiem U, Heppner HJ, Pientka L. Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging 2011; 28:519-37.
96. Fung HB, Monteagudo-Chu MO. Community-acquired pneumonia in the elderly. Am J Geriatr Pharmacother 2010; 8:47-62.
97. Torres OH, Gil E, Pacho C, Ruiz D. Update of pneumonia in the elderly. Rev Esp Geriatr Gerontol 2013; 48:72-8.
98. Mundy LM, Leet TL, Darst K, Schnitzler MA, Dunagan WC. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124:883-9.
99. Givens JL, Jones RN, Shaffer ML, Kiely DK, Mitchell SL. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 2010; 170:1102-7.
100. Cillóniz C, Polverino E, Ewig S, Aliberti S, Gabarrús A, Menéndez R, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 2013; 144:999-1007.
101. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
102. Lim WS, van der Eerden MM, Laing R, Boersma WG, Kartalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-82.
103. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006; 61:419-24.
104. Mynt PK, Kamath AV, Vowler SL, Masey DN, Harrison B. Severity assesment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients. Should SOAR (systolic blood pressure, oxygenation, age and respiratorty rate) criteria be used in older people?. A compilation study of two prospective cohorts. Age and Ageing 2006; 35:286-291.
105. Espãa PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174:1249-56.
106. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: A tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47:375-84.
107. Llorens P, Murcia-Zaragoza J, Sanchez-Paya J, Laghzaoui F, Reus S, Carratala-Perales JM, et al. Evaluación de un modelo mutidisciplinar de hospitalización alternativa a la hospitalización convencional en la neumonia adquirida en la comunidad. Emergencias 2011; 23:167-174.
108. Juan A, Jacob J, Llopis F, Gomez-Vaquero C, Ferré C, Perez-Mas JR, et al. Análisis de la seguridad y la eficacia de la unidad de corta estancia en el tratamiento de la neumonía adquirida en la comunidad. Emergencias 2011; 23:175-82.
109. Mujal Martínez A, Solá Aznar J, Hernández Ávila M, Aragüás Flores C, Machado Sicilia ML, Oristrell Salvá J. Eficacia y seguridad del tratamiento antibiótico domiciliario endovenoso en pacientes con patología infecciosa procedentes del servicio de urgencias. Emergencias 2013; 25:31-6.
110. Juan A, Ferré C, Llopis F, Jacob J, Bardés I, Salazar A. La unidad de corta estancia como alternativa a la hospitalización convencional en el tratamiento de la neumonia adquirida en la comunidad en la población mayor de 75 años. Rev Esp Geriatr Gerontol 2001; 46:213-216.
111. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis 2010; 51:S198-208.
112. Mirón M, Estrada O, Gonzalez-Ramallo VJ. Protocolos de tratamiento antimicrobiano domiciliario endovenoso (TADE). SEMI. 2008; Capitulo XI:149-159.
113. Murder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management and prevention. Am J Med 1998; 105:319-30.
114. Mylotte JM, Naughton B, Saludades Ch, Mászarovics Z. Validation and application of the pneumonia prognosis index to nursing home residents with pneumonia. J Am Geriatr Soc 1998; 46:1538-44.
115. Mehr DR, Binder EF, Kruse RL, Zweig SC, Madsen R, Popejoy L, et al. Predicting mortality in nursing home residents with lower respiratory tract infection: the Missouri LRI study. JAMA 2001; 286:2427-36.
116. Rodriguez C, Salgado D, López A. Neumonía en pacientes institucionalizados. Guía de buena práctica clínica en geriatría. Neumonías 2006. ISBN 84-7592-803-X
117. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to stability in Patients Hospitalized with Community-Acquired Pneumonia: Implications from Practice Guidelines. JAMA 1998; 279:1452-1457.
118. Domínguez A, Izquierdo C, Salleras L, Ruiz L, Sousa D, Bayas JM, et al; Working Group for the Study of Prevention of CAP in the Elderly. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010; 36:608-14.
119. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; 23:CD000422
120. Fung HB, Monteagudo-Chu MO. Community-acquired pneumonia in the elderly. Am J Geriatr Pharmacother 2010; 8:47-62.
121. Picazo J, González-Romo F, García-Rojas A, Pérez-Trallero E, Gil Gregorio P, de la Cámara R, et al. Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions. Rev Esp Quimioter 2013; 26:232-52.
122. Pace CC, McCullough GH. The association between oral microorgansims and aspiration pneumonia in the institutionalized elderly: review and recommendations. Dysphagia 2010; 25:307-22.
123. Ebihara S, Ebihara T, Gui P, Osaka K, Sumi Y, Kohzuki M. Thermal Taste and Anti-Aspiration Drugs: a Novel Drug Discovery against Pneumonia. Curr Pharm Des 2013; 19:1-5.